Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

被引：2
|
作者：
Davies, Andrew J. [1 ,2 ]
Caddy, Josh [3 ]
McLaughlin, Katy [3 ]
Wignall, Christopher [3 ]
Waugh, Robert [3 ]
Collins, Graham P. [4 ]
Stanton, Louise [3 ]
Saunders, Geoff N. [3 ]
Cummin, Thomas [5 ]
Schuh, Anna [6 ]
Ardeshna, Kirit M. [7 ]
McMillan, Andrew K. [8 ]
Radford, John [9 ,10 ]
Lewis, David John [11 ]
Coleman, Adam R. [1 ]
Griffiths, Gareth [3 ]
Burton, Cathy [12 ]
Barrans, Sharon [12 ]
Johnson, Peter [1 ,13 ]
机构：
[1] Canc Res UK Expt Canc Med Ctr UK, Southampton, Hants, England
[2] Southampton Canc Res UK Ctr, Southampton, Hants, England
[3] Univ Southampton, Canc Res UK Southampton Clin Trials Unit, Southampton, Hants, England
[4] Churchill Hosp, Oxford Canc & Haematol Ctr, Oxford, England
[5] Portsmouth Hosp Univ NHS Trust, Portsmouth, Hants, England
[6] Univ Oxford, Oxford Mol Diagnost Ctr, Oxford, England
[7] Univ Coll London Hosp NHS Fdn Trust, Dept Haematol, London, England
[8] Nottingham Univ Hosp NHS Trust, Nottingham, England
[9] Univ Manchester, NIHR Clin Res Facil, Manchester, Lancs, England
[10] Christie NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
[11] Derriford Hosp, Dept Haematol, Plymouth, Devon, England
[12] Leeds Canc Ctr, Haematol Malignancy Diagnost Serv, Leeds, W Yorkshire, England
[13] Univ Southampton, Fac Med, Sch Canc Sci, Southampton, Hants, England
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-163499
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：9478 / 9479
页数：2
相关论文
共 50 条
  • [41] Phase II/III Study of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab (R-CHOP) Versus Biweekly CHOP with Rituximab (R-Bi-CHOP) In Untreated Advanced-Stage Indolent B-Cell Lymphoma: Japan Clinical Oncology Group (JCOG) 0203 Trial
    Watanabe, Takashi
    Morishima, Yasuo
    Shibata, Taro
    Maseki, Nobuo
    Kinoshita, Tomohiro
    Suzuki, Takayo
    Yamaguchi, Motoko
    Ando, Kiyoshi
    Ogura, Michinori
    Taniwaki, Masafumi
    Uike, Naokuni
    Takeuchi, Kengo
    Nawano, Shigeru
    Terauchi, Takashi
    Tsukasaki, Kunihiro
    Hotta, Tomomitsu
    Tobinai, Kensei
    BLOOD, 2010, 116 (21) : 193 - 193
  • [42] Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Label, Single Arm, Phase II Trial
    Oki, Yasuhiro
    Ewer, Michael S.
    Lenihan, Daniel J.
    Fisch, Michael J.
    Hagemeister, Fredrick B.
    Fanale, Michelle
    Romaguera, Jorge
    Pro, Barbara
    Fowler, Nathan
    Younes, Anas
    Astrow, Alan B.
    Huang, Xuelin
    Kwak, Larry W.
    Samaniego, Felipe
    McLaughlin, Peter
    Neelapu, Sattva S.
    Wang, Michael
    Fayad, Luis E.
    Durand, Jean-Bernard
    Rodriguez, M. Alma
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (03): : 152 - 158
  • [43] A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma
    Micallef, Ivana N. M.
    Kahl, Brad S.
    Maurer, Matthew J.
    Dogan, Ahmet
    Ansell, Stephen M.
    Colgan, Joseph P.
    Geyer, Susan
    Inwards, David J.
    White, William L.
    Habermann, Thomas M.
    CANCER, 2006, 107 (12) : 2826 - 2832
  • [44] The POLARIX Study: Polatuzumab Vedotin With Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone vs Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 10 - 11
  • [45] Prognostic Significance of Survivin Expression in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Report from the International DLBCL Rituximab-CHOP Consortium Program
    Liu, Zhiyu
    Xu-Monette, Zijun Y.
    Cao, Xin
    Visco, Carlo
    Tzankov, Alexander
    Montes-Moreno, Santiago
    Dybkaer, Karen
    Chiu, April
    Orazi, Attilio
    Zu, Youli
    Bhagat, Govind
    Richards, Kristy L.
    Hsi, Eric D.
    Choi, William W. L.
    van Krieken, J. Han
    Huh, Jooryung
    Ai, Weiyun
    Ponzoni, Maurilio
    Ferreri, Andres J. M.
    Farnen, John P.
    Moller, Michael B.
    Winter, Jane N.
    Piris, Miguel A.
    Medeiros, L. Jeffrey
    Young, Ken H.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S216 - S216
  • [46] A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab As Maintenance Therapy Following R-CHOP Chemotherapy for Patients with High Risk Diffuse Large B-Cell Lymphoma
    Reddy, Nishitha M.
    Simons, Rhea M.
    Caldwell, Meghan E.
    Chen, Heidi
    Jagasia, Madan
    Morgan, David S.
    Park, Steven I.
    Greer, John P.
    Richards, Kristy L.
    BLOOD, 2012, 120 (21)
  • [47] Promising results of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma
    Micallef, I. N.
    Maurer, M.
    Nikcevich, D.
    Cannon, M.
    Moore, D.
    Kurtin, P.
    Schaefer, E.
    Witzig, T.
    ANNALS OF ONCOLOGY, 2008, 19 : 161 - 161
  • [48] Safety and Efficacy of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of the Phase II Avr-CHOP Study
    Hawkes, Eliza A.
    Chong, Geoffrey
    Smith, Charmaine
    Lee, Sze-Ting
    Churilov, Leonid
    McKendrick, Joseph
    Renwick, William
    Blombery, Piers
    Nelson, Niles Elizabeth
    Fancourt, Tineke
    Hawking, Joanne
    Lin, Wendi
    Scott, Andrew M.
    Barraclough, Allison
    Wight, Joel
    Grigg, Andrew
    Keane, Colm
    Fong, Chun Yew
    Manos, Kate
    BLOOD, 2020, 136
  • [49] Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)
    Mounier, N
    Briere, J
    Gisselbrecht, C
    Emile, JF
    Lederlin, P
    Sebban, C
    Berger, F
    Bosly, A
    Morel, P
    Tilly, H
    Bouabdallah, R
    Reyes, F
    Gaulard, P
    Coiffier, B
    BLOOD, 2003, 101 (11) : 4279 - 4284
  • [50] Bendamustine in association with rituximab for first-line treatment of diffuse large B-cell lymphoma in frail patients ineligible for R-CHOP/R-CHOP-like treatments
    Castelli, Roberto
    Gidaro, Antonio
    Deliliers, Giorgio L.
    Bergamaschini, Luigi
    ANTI-CANCER DRUGS, 2021, 32 (03) : 323 - 329
12345